These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34016993)

  • 1. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
    Vahdat LT; Schmid P; Forero-Torres A; Blackwell K; Telli ML; Melisko M; Möbus V; Cortes J; Montero AJ; Ma C; Nanda R; Wright GS; He Y; Hawthorne T; Bagley RG; Halim AB; Turner CD; Yardley DA
    NPJ Breast Cancer; 2021 May; 7(1):57. PubMed ID: 34016993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.
    Hasanov M; Rioth MJ; Kendra K; Hernandez-Aya L; Joseph RW; Williamson S; Chandra S; Shirai K; Turner CD; Lewis K; Crowley E; Moscow J; Carter B; Patel S
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
    Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
    Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
    Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
    Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
    Li Q; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):938-41. PubMed ID: 26887625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
    J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
    Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
    Rugo HS; Roche H; Thomas E; Chung HC; Lerzo GL; Vasyutin I; Patel A; Vahdat L
    Clin Breast Cancer; 2018 Dec; 18(6):489-497. PubMed ID: 30153978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.